Progyny (PGNY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Executive summary
The annual meeting will be held virtually on May 21, 2026, with stockholders able to participate online and vote on key proposals.
Five main proposals are up for vote: election of three directors, ratification of the auditor, advisory approval of executive compensation, and two amendments to eliminate supermajority voting requirements.
Stockholders can vote online, by phone, or by mail, and may revoke their proxy at any time before the final vote.
The board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Elect three Class I directors to serve until 2029.
Proposal 2: Ratify Ernst & Young LLP as independent auditor for 2026.
Proposal 3: Advisory (non-binding) approval of executive compensation (say-on-pay).
Proposal 4: Amend Certificate of Incorporation to eliminate certain supermajority voting requirements, lowering thresholds to a simple majority.
Proposal 5: Amend Certificate of Incorporation to eliminate the default supermajority voting requirement for certain business combinations.
Stockholder proposals for the 2027 meeting must be submitted by December 11, 2026 for inclusion in proxy materials.
Board of directors and corporate governance
The board consists of ten members divided into three staggered classes, with a majority deemed independent under Nasdaq standards.
Board leadership includes an executive chairman and a lead independent director.
Committees include audit, compensation, and nominating/governance, all composed of independent directors.
The board regularly reviews its leadership structure and committee composition.
Directors are evaluated on integrity, expertise, and ability to serve stockholder interests.
Latest events from Progyny
- Proxy covers director elections, auditor ratification, pay reforms, and governance changes.PGNY
Proxy filing10 Apr 2026 - Votes will address director elections, auditor ratification, and governance amendments.PGNY
Proxy filing10 Apr 2026 - Strong utilization and new product launches drive growth amid stable competition and tech investment.PGNY
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Stable growth, high retention, and new market expansion drive a positive long-term outlook.PGNY
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Record 2025 revenue and margin gains, with 2026 guidance projecting further growth.PGNY
Q4 202526 Feb 2026 - Q2 revenue up 9%, guidance cut 5%, with record margins and $100M added to share buybacks.PGNY
Q2 20242 Feb 2026 - Targets $2.4B+ revenue and 20% CAGR by 2028, fueled by new women's health products.PGNY
Investor Day 20242 Feb 2026 - Utilization rebounded after a Q1 dip, with strong membership growth and a favorable outlook.PGNY
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Q3 revenue up 2%, net income and margins down; new clients, services, and buybacks offset client loss risk.PGNY
Q3 202414 Jan 2026